Drug Profile


Alternative Names: M22; Remyelinating-monoclonal-antibody-Acorda-Therapeutics; sHIgM22

Latest Information Update: 13 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mayo Clinic
  • Developer Acorda Therapeutics
  • Class Monoclonal antibodies
  • Mechanism of Action Myelin protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 21 Sep 2017 Acorda Therapeutics completes a phase I trial in Multiple sclerosis in USA (IV) (NCT02398461)
  • 07 Sep 2016 rHIgM22 is still in phase I trials for Multiple sclerosis in USA (Acorda Therapeutics pipeline, September 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Multiple-sclerosis in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top